Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Excellent service Love the way it makes me feel
Give our clinic a call today to schedule your personal consultation
Recently, in February 2025, the FDA removed the medications from the shortage list, but they can still be unavailable depending on your location
US$ 21.59
US$ 29.21
US$ 28.54
US$ 28.63
US$ 21.34
US$ 27.90
US$ 25.70
US$ 23.07
